Tomáš Pika

2.4k total citations
67 papers, 336 citations indexed

About

Tomáš Pika is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Tomáš Pika has authored 67 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Hematology, 43 papers in Molecular Biology and 33 papers in Oncology. Recurrent topics in Tomáš Pika's work include Multiple Myeloma Research and Treatments (50 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (20 papers) and Cancer Treatment and Pharmacology (12 papers). Tomáš Pika is often cited by papers focused on Multiple Myeloma Research and Treatments (50 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (20 papers) and Cancer Treatment and Pharmacology (12 papers). Tomáš Pika collaborates with scholars based in Czechia, Spain and Greece. Tomáš Pika's co-authors include Jiří Minařík, Vlastimil Ščudla, Jaroslav Bačovský, Roman Hájek, Marián Hajdúch, Petr Džubák, Kateřina Langová, Bettina Maier, Vladimír Maisnar and Stefan Schönland and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Tomáš Pika

54 papers receiving 328 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tomáš Pika Czechia 11 224 222 129 68 31 67 336
Miriam Hobbs United States 7 139 0.6× 129 0.6× 80 0.6× 75 1.1× 15 0.5× 26 225
Bart Barlogie United States 5 192 0.9× 215 1.0× 107 0.8× 63 0.9× 45 1.5× 9 290
Vladimír Maisnar Czechia 13 393 1.8× 323 1.5× 238 1.8× 92 1.4× 9 0.3× 80 467
Tobias Dittrich Germany 12 115 0.5× 385 1.7× 125 1.0× 167 2.5× 77 2.5× 27 439
Gabriele Sarais Italy 7 88 0.4× 466 2.1× 119 0.9× 129 1.9× 137 4.4× 7 505
Eva Medvedova United States 10 567 2.5× 536 2.4× 373 2.9× 120 1.8× 39 1.3× 47 737
RA Kyle United States 9 436 1.9× 309 1.4× 207 1.6× 84 1.2× 14 0.5× 9 503
Enrica Borsi Italy 12 239 1.1× 243 1.1× 157 1.2× 34 0.5× 3 0.1× 26 392
F. G. C. Jones United Kingdom 11 122 0.5× 128 0.6× 39 0.3× 82 1.2× 5 0.2× 18 289
David Siegel United States 9 390 1.7× 341 1.5× 265 2.1× 43 0.6× 7 0.2× 23 529

Countries citing papers authored by Tomáš Pika

Since Specialization
Citations

This map shows the geographic impact of Tomáš Pika's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomáš Pika with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomáš Pika more than expected).

Fields of papers citing papers by Tomáš Pika

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomáš Pika. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomáš Pika. The network helps show where Tomáš Pika may publish in the future.

Co-authorship network of co-authors of Tomáš Pika

This figure shows the co-authorship network connecting the top 25 collaborators of Tomáš Pika. A scholar is included among the top collaborators of Tomáš Pika based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomáš Pika. Tomáš Pika is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Štork, Martin, Ivan Špıčka, Jakub Radocha, et al.. (2023). Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis. Annals of Hematology. 102(6). 1501–1511. 6 indexed citations
3.
Pour, Luděk, Ivan Špıčka, Jakub Radocha, et al.. (2023). P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS. HemaSphere. 7(S3). e0151603–e0151603. 1 indexed citations
4.
Štork, Martin, Sabina Ševčı́ková, Tomáš Jelı́nek, et al.. (2022). Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas. Biomedicines. 10(10). 2535–2535. 2 indexed citations
5.
Maisnar, Vladimír, Luděk Pour, Ivan Špıčka, et al.. (2022). Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data. Clinical Lymphoma Myeloma & Leukemia. 23(2). 145–153. 4 indexed citations
6.
Minařík, Jiří, Jakub Radocha, Alexandra Jungová, et al.. (2022). Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy. Cancers. 14(20). 5165–5165. 5 indexed citations
7.
Minařík, Jiří, et al.. (2021). A rare case of bifocal, extramedullary and hyposecretory relapse of multiple myeloma. SHILAP Revista de lepidopterología. 9(8). e04570–e04570. 1 indexed citations
8.
Pika, Tomáš, et al.. (2019). Mass Spectrometry Amyloid Typing Is Reproducible across Multiple Organ Sites. BioMed Research International. 2019. 1–9. 19 indexed citations
9.
10.
Minařík, Jiří, et al.. (2017). CD38‐negative relapse in multiple myeloma after daratumumab‐based chemotherapy. European Journal Of Haematology. 99(2). 186–189. 14 indexed citations
11.
12.
Minařík, Jiří, et al.. (2017). Differential diagnosis of monoclonal gammopathies from the point of clinical practiceI. Malignant monoclonal gammopathies. Interní medicína pro praxi. 19(5). 274–278. 1 indexed citations
13.
Minařík, Jiří, Jan Hrbek, Tomáš Pika, et al.. (2016). Prospective comparison of conventional radiography, low-dose computed tomography and magnetic resonance imaging in monoclonal gammopathies. Biomedical Papers. 160(2). 305–309. 7 indexed citations
14.
15.
Minařík, Jiří, Tomáš Pika, Jaroslav Bačovský, & Vlastimil Ščudla. (2013). Kryoglobulinemická vaskulitida u nemocného s mnohočetným myelomem. Interní medicína pro praxi. 14(12). 478–480.
16.
Minařík, Jiří, et al.. (2012). Prognostic Value of Hepatocyte Growth Factor, Syndecan-1, and Osteopontin in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance. The Scientific World JOURNAL. 2012. 1–6. 13 indexed citations
17.
Minařík, Jiří, Vlastimil Ščudla, Tomáš Pika, et al.. (2010). Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis. Leukemia Research. 35(1). 44–48. 5 indexed citations
18.
Minařík, Jiří, et al.. (2009). Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib. European Journal Of Haematology. 83(6). 528–534. 3 indexed citations
19.
Pika, Tomáš, et al.. (2009). UNUSUAL MANIFESTATION OF MULTIPLE MYELOMA: FOCAL AFFECTION OF CENTRAL NERVOUS SYSTEM IN A PATIENT WITH CHRONIC LYMPHOCYTIC LEUKAEMIA. Biomedical Papers. 153(4). 271–273. 2 indexed citations
20.
Pika, Tomáš, Jiří Minařík, Marie Budı́ková, et al.. (2008). THE CORRELATION OF SERUM IMMUNOGLOBULIN FREE LIGHT CHAIN LEVELS AND SELECTED BIOLOGICAL MARKERS IN MULTIPLE MYELOMA. Biomedical Papers. 152(1). 61–64. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miriam Hobbs Breakdown of academic impact, for papers by Bart Barlogie Breakdown of academic impact, for papers by Vladimír Maisnar Breakdown of academic impact, for papers by Tobias Dittrich Breakdown of academic impact, for papers by Gabriele Sarais Breakdown of academic impact, for papers by Eva Medvedova Breakdown of academic impact, for papers by RA Kyle Breakdown of academic impact, for papers by Enrica Borsi Breakdown of academic impact, for papers by F. G. C. Jones Breakdown of academic impact, for papers by David Siegel
Rankless by CCL
2026